



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

December 27, 2022

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

Scrip code: 500672

Dear Sir/ Madam,

Sub.: Intimation of meeting of the Board of Directors of Novartis India Limited (“the Company”) and Closure of Trading Window

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, February 8, 2023, to, *inter alia*, consider and approve the Unaudited Financial Results of the Company for the third quarter ending on December 31, 2022.

In this connection, please note that pursuant to the ‘Code of Conduct to regulate, monitor and report share trading by Designated Persons and their immediate relatives’ (“Code”) read with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the Trading Window for dealing in shares of the Company by Designated Persons shall remain closed with effect from Wednesday, December 28, 2022 to Friday, February 10, 2023 (both days inclusive).

You are requested to kindly take note of the above information.

Thanking You.

Yours Sincerely,

For Novartis India Limited

Malpani
Nikhil

Digitally signed by Malpani Nikhil
DN: dc=com, dc=novartis, ou=people,
ou=GIT, serialNumber=3079258,
cn=Malpani Nikhil
Date: 2022.12.27 14:49:36 +05'30'

Nikhil Malpani
Company Secretary and Compliance Officer